Suppr超能文献

失调的miR-369-3p表达的减弱通过调节核苷酸糖转运蛋白SLC35F5使非小细胞肺癌细胞对顺铂敏感。

Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5.

作者信息

Hao Guang-Jun, Ding Yan-Hui, Wen Hui, Li Xiao-Feng, Zhang Wei, Su Hu-Yan, Liu Dong-Mei, Xie Nian-Lin

机构信息

Department of Oncology, First Hospital of Yulin City, Yulin 719000, PR China.

Department of Oncology, First Hospital of Yulin City, Yulin 719000, PR China; Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, PR China.

出版信息

Biochem Biophys Res Commun. 2017 Jul 1;488(3):501-508. doi: 10.1016/j.bbrc.2017.05.075. Epub 2017 May 13.

Abstract

Deregulation of the microRNAs (miRNAs), a cluster of important posttranscriptional regulators, has been frequently associated with lung cancer (LCa). However, the emerging mechanism for how miRNAs is linked causally in the development of LCa chemoresistance is poorly understood. Herein, we established for the time the up-regulation of miR-369-3p in cisplatin (DDP)-resistant nonsmall cell lung cancer (NSCLC) tissues and cells. Its deregulation was found to be correlated to the magnitude of malignancy in well-characterized LCa cells. Functionally, inhibition of miR-369-3p sensitized LCa cells to DDP and suppressed the invasive capability in the presence of DDP treatment, whereas miR-369-3p overexpression promoted DDP resistance and thereby enhanced LCa cells invasiveness. Mechanistically, bioinformatics coupled with luciferase and gain-of-function, loss-of-function assays revealed that miR-369-3p may regulate DDP chemoresistance by directly targeting the 3' untranslated region (UTR) of human solute carrier 35F5 (SLC35F5), as application of miR-369-3p inhibitors or reintroduction of epigenetically silenced SLC35F5 both individually sensitized LCa cells to DDP, but combined treatment with miR-369-3p inhibitors and SLC35F5 overexpression failed to sensitized LCa cells further to DDP-elicited cell death. Our results provide evidence that the oncomiR effect of miR-369-3p may be mediated through disrupting the nucleotide sugar transportation and that SLC35F5 is a key effector of this chemoresistance-promoting activity.

摘要

微小RNA(miRNA)是一类重要的转录后调节因子,其失调常与肺癌(LCa)相关。然而,miRNA在LCa化疗耐药发生过程中因果关联的新机制仍知之甚少。在此,我们首次证实顺铂(DDP)耐药的非小细胞肺癌(NSCLC)组织和细胞中miR-369-3p上调。在特征明确的LCa细胞中,其失调与恶性程度相关。功能上,抑制miR-369-3p可使LCa细胞对DDP敏感,并在DDP处理下抑制侵袭能力,而miR-369-3p过表达则促进DDP耐药,从而增强LCa细胞的侵袭性。机制上,生物信息学结合荧光素酶及功能获得和功能缺失实验表明,miR-369-3p可能通过直接靶向人类溶质载体35F5(SLC35F5)的3'非翻译区(UTR)来调节DDP化疗耐药,因为单独应用miR-369-3p抑制剂或重新引入表观遗传沉默的SLC35F5均可使LCa细胞对DDP敏感,但联合使用miR-369-3p抑制剂和SLC35F5过表达并不能使LCa细胞对DDP诱导的细胞死亡更敏感。我们的结果表明,miR-369-3p的致癌miRNA效应可能是通过破坏核苷酸糖转运介导的,且SLC35F5是这种促进化疗耐药活性的关键效应因子。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验